BEIJING, China — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb clinical study of novel BTK inhibitor orelabrutinib has met the primary endpoint in patients with systemic lupus erythematosus (SLE). InnoCare has also...
Latest News
DURHAM, N.C. — For too long, cancer treatment has been a double-edged sword – the very treatments designed to kill cancer cells often wrought havoc on healthy ones too. But a new study published online Oct. 30 in Immunity, a Cell Press journal, unveils an approach to cancer treatment that...
Tucson, Arizona – Mosquito-borne illnesses remain a formidable challenge threatening millions of people each year with diseases such as malaria, dengue, zika and chikungunya. To develop a mosquito control strategy with a minimal ecological footprint, biochemists and entomologists from the University of Arizona have pioneered a novel approach by harnessing...
LONDON, UK – Hyris Ltd, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation to sophisticated laboratories. The prototype can diagnose a mosquito for insecticide resistance at the field site three...
Celgene International Sàrl (NASDAQ: CELG) announced that data from multiple studies presented at the 14th Congress of the European Society of Hematology demonstrate that REVLIMID provides powerful and sustained responses in patients with multiple myeloma. These key presentations support the advantage of active long-term disease control along with manageable safety...
A new collaboration between UW Health, the Waisman Center, and the UW School of Medicine and Public Health aims to discover, diagnose, and ultimately better understand rare genetic diseases. The UW Center for Human Genomics and Precision Medicine at the UW School of Medicine and Public Health recently opened its...
SAN FRANCISCO and SUZHOU, China – Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Ascentage Pharma (6855.HK), today announced a multifaceted strategic collaboration. This collaboration includes: i) the joint commercialization of HQP1351...
ROCKVILLE, Md. and SUZHOU, China — Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and Xuanzhu Biopharma, today announce that they entered into a clinical trial collaboration and supply agreement for...
ROCKVILLE, Md. and SUZHOU, China — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for IBI351 (KRAS G12C inhibitor) has been...
SAN FRANCISCO and SUZHOU, China – Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the Center for Drug Evaluation (CDE) of China’s Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy...